Cullinan Therapeutics Inc (CGEM) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Cullinan Therapeutics Inc   (NASDAQ: CGEM)


Cullinan Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Cullinan Therapeutics Inc's ROI in the second quarter of 2026?
Cullinan Therapeutics Inc recorded a cumulative net loss of $-205 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -52.63%.

Within the Healthcare sector 413 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2191 to 3733.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -31.33 % -28.91 % -16.9 % -3.4 % 13.01 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 323 369 411 453 494
Return On Investment (TTM) -52.63 % -51.22 % -46.02 % -41.49 % -36.51 %
CGEM's Overall Ranking # 3733 # 2191 # 3338 # 3221 # 2916
Seq. Investment Change TTM -9.88 % -9.69 % -8.56 % -7.74 % -6.69 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -205 -221 -220 -217 -207

CGEM Company Profile >> Back to CGEM Roi Comparisons >> See Annual CGEM Return On Investment



Return On Investment CGEM's Ranking
Within: No.
Industry # 65
Sector # 414
Overall # 3733

Return On Investment Statistics
High Average Low
22.89 %
-22.35 %
-79.25 %
(Jun 30 2022)   (Mar 31 2014)



  News about Cullinan Therapeutics Inc Return on Investment ROI

Cullinan Therapeutics Launches Innovative Global Phase 1 Clinical Trial for Systemic Lupus Erythematosus,

September 17, 2024

Cullinan Therapeutics Embarks on Groundbreaking Global Phase 1 Clinical Trial for Systemic Lupus ErythematosusIn a significant leap forward for autoimmune disease research, Cullinan Therapeutics, a division of Cullinan Oncology Inc. (NASDAQ: CGEM), has received approval to initiate its first global Phase 1 clinical trial of CLN-978. This investigational therapy is aimed at combatting systemic lupus erythematosus (SLE), a chronic, often debilitating autoimmune disease that affects millions worldwide.The Phase 1 clinical trial is poised to rigorously evaluate the safety, pharmacokinetics, and initial clinical activity of CLN-978 in SLE patients. This milestone speaks volumes about the potential impact of CLN-978, which seeks to fill a substantial void in the current treatment landscape for systemic lupus erythematosus. SLE presents a significant challenge due to its complex pathophysiology and the current lack of highly effective, targeted therapies.

Zipalertinib A New Hope for Non-Small Cell Lung Cancer Patients with Challenging EGFR Exon 20 Insertions

September 14, 2024

for CSIMarket.com : The emergence of targeted therapies has revolutionized the treatment landscape for non-small cell lung cancer (NSCLC), especially for patients harboring specific mutations in the epidermal growth factor receptor (EGFR). A pivotal Phase 2b study of Zipalertinib, presented at ESMO 2024 by Cullinan Therapeutics, revealed promising updated data indicating a consistent response rate and a manageable safety profile. This article synthesizes key findings from the study and discusses the implications for clinical practice. Non-small cell lung cancer (NSCLC) remains one of the leading causes of cancer mortality worldwide. Among the various genetic alterations associated with NSCLC, mutations in the EGFR, particularly exon 20 insertions, pose a significant therapeutic challenge. Traditional EGFR tyrosine kinase inhibitors have shown limited efficacy against these mutations, leading to the exploration of novel therapies. Zipalertinib, a potent oral EGFR inhibitor, has emerged as a potential treatment option, particularly for patients who have progressed on prior therapies such as amivantamab. Study Overview: Cullinan Therapeutics presented updated data from Module C of the pivotal Phase 2b study, which evaluated the efficacy and safety of Zipalertinib in patients with NSCLC and EGFR exon 20 insertion mutations. The study consisted of patients who had already received amivantamab, an EGFR-targeting monoclonal antibody, and then demonstrated disease progression.





Financial Statements
Cullinan Therapeutics Inc's II. Quarter Investments $ 323 Millions CGEM's Balance sheet
Cullinan Therapeutics Inc's II. Quarter Income $ -54 Millions Quarterly CGEM's Income Statement
CGEM's Income by Division See CGEM's Income by Division


CGEM Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 409 590 454 535 426
Y / Y Investment Growth -30.76 % 30 % -15.13 % 25.64 % -
Net Income in Millions -220 -168 -155 109 -67
Y / Y Net Income Growth - - - - -
Annual Return On Investment -53.8 % -28.39 % -34.16 % 20.41 % -15.85 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
CGEM's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for CGEM's Competitors
Subscribers only: Roi for Cullinan Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for CGEM's Customers

Other Ratios
CGEM's Roa CGEM's Inventory Turnover Ratio CGEM's Growth Rates CGEM's Dividend Statistics
CGEM's Profitability Ratios CGEM's Asset Turnover Ratio CGEM's Dividend Growth
CGEM's Roe CGEM's Valuation Ratios CGEM's Financial Strength Ratios CGEM's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-26T07:39:22+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.